Good morning, and welcome to the Assertio Holdings, Inc. and Spectrum Pharmaceuticals, Inc. conference call. All participants will be in listening only mode. All lines have been placed on mute to prevent any background noise. If you require operator assistance at any time, please press star zero. After today's presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference over to Matt Kreps from Darrow Associates, Investor Relations for Assertio. Please go ahead. Thank you, Brianna. Good morning, and thank you to all of you for joining us on this special conference call regarding the definitive agreement announced earlier today, pursuant to which Assertio will acquire all outstanding shares of Spectrum in an all-stock and contingent value rights transaction. The joint press release with details of the agreement is now available on the investor pages of both companies. I'd encourage you to review the release and related SEC filings. With me today are Dan Peisert, President and CEO of Assertio, and Tom Riga, President and CEO of Spectrum. After prepared remarks from Dan and Tom, we will open the call for your questions. During this call, management will make projections and other forward-looking statements regarding future performance. Such forward-looking statements are not guarantees of future performance, involve risks and uncertainties, and speak only as of the current date. Please refer to the cautionary statement in this morning's joint press release for more information on the risks related to any forward-looking statements that we may make. These and other risks are more fully described in the Risk Factors section and other sections of each of Assertio's and Spectrum's annual reports on Form 10-K. Actual results may differ materially from those projected in the forward-looking statements. Assertio and Spectrum specifically disclaim any intent or obligation to update these forward-looking statements except as required by law. With that, I'll now turn the call over to Dan. Thank you, Matt. Good morning. Today is an important day for both Assertio and Spectrum. We're very excited to be announcing that we've entered into a definitive agreement to acquire Spectrum Pharmaceuticals in an all-stock and CVR transaction. Through this transaction, we combine two of the fastest growing small cap companies in the specialty pharmaceutical industry. One with a new promotional platform targeting broad reach and increased frequency that can be applied across multiple therapeutic categories, and the other focused on oncology in the midst of what we believe is a highly successful product launch in ROLVEDON. Together, we will have two synergistic and light infrastructure commercial platforms in a diversified portfolio of assets. I'm pleased to be joined on the call by Tom Riga, CEO of Spectrum. Before getting into the details of the transaction and rationale, let me first say thank you to the teams from both companies for working extremely hard over these last few weeks and months to get to this point. This transaction accelerates our strategy to diversify and extend the duration of our portfolio, strengthens our commercial infrastructure with two complementary and scalable platforms, and increases our financial strength and access to the capital markets for future M&A. This transaction is expected to accelerate and diversify Assertio's growing revenues, while also significantly extending the portfolio's weighted average patent life. Combined, we will have four commercial growth assets in Indocin, ROLVEDON, SYMPAZAN, and Otrexup. We believe this combined portfolio of products offers a pathway to more than doubling our existing revenue base with the near-term potential to have two products generating greater than $100 million in revenues each, neither of which we expect to be more than 45% of the pro forma product revenue. We'll have three growth assets in ROLVEDON, SYMPAZAN, and Otrexup, with issued and lifted patents well into the next decade. We intend to retain the majority of Spectrum's commercial team and infrastructure as part of the combination of our two companies. This will expand each company's sales capabilities and create complementary omnichannel digital and in-person commercial platforms with a proven expertise in direct contracting with the end customers. The Spectrum team has done a remarkable job with the launch of ROLVEDON. Combined, we believe we can certainly accelerate the path to profitability and possibly accelerate the trajectory through a broader reach than what the in-person team has been able to do to date to drive awareness of ROLVEDON's unique benefits to both physicians as well as the purchasing managers in a community oncology setting. In the last three years, Assertio has integrated two product acquisitions and a company acquisition. We were able to integrate Zyla into our business during the peak of the COVID pandemic in the spring of 2020. With all three of those transactions, we were able to integrate the new assets without interruption and delivered significant financial synergies to our shareholders. I am confident that we have the experience and capability to do the same with Spectrum. We intend to add approximately $60 million of annual operating expenses to Assertio's existing expense base. This compares to the $80 million annual run rate as implied from Spectrum's reported figures in the fourth quarter of 2022, their first quarter as a full commercial organization. We believe that this will significantly accelerate the profitability of ROLVEDON, and we expect the transaction to be highly accretive in to 2024 Adjusted EBITDA, adjusted EPS, and free cash flow. This pro forma profile should enhance our access to the capital markets at a lower cost of capital than either company had on a standalone basis and accelerate our future M&A strategies so we can leverage both our platforms with complementary assets, of which Tom and I have already discussed a number of attractive targets. This is an all-stock and CVR transaction. Upon the close, Assertio shareholders should own approximately 65% of the combined company, Spectrum shareholders own approximately 35%. Spectrum shareholders will receive 0.1783 shares of Assertio common stock for each share of Spectrum common stock that they own. In addition, there is a $0.20 CVR tied to the net sales of ROLVEDON in calendar years 2024 and 2025 that may be paid in cash or stock at Assertio's election. Assertio expects to retire Spectrum's existing debt at or prior to closing, leaving the remaining $40 million of Assertio's convertible bonds outstanding as the only debt in the combined entity. The combined company will have a six-member board consisting of all five Assertio directors and one new board member from Spectrum. I will continue to serve as chief executive officer and a member of the board. The deal has been approved and recommended by the boards of both Assertio and Spectrum. The corporate headquarters will be here in Lake Forest, Illinois, where Assertio is headquartered. We expect the transaction to close in the third quarter of 2023, subject to the approval of both company shareholders, regulatory approval, and other customary closing conditions. For the benefit of the Spectrum shareholders, employees, and others less familiar with Assertio, we are a therapeutic area agnostic commercial pharmaceutical company. For the past 30 months or so, we've been building and curating a low-cost digital, non-personal promotional model to promote our assets. We migrated to this model during the pandemic, and it was specifically designed to reflect the new realities of our environment, where the physicians we were marketing to had less and less time to engage with our traditional in-person sales representatives, and we were facing ever-increasing payer influence. We shifted our allocation of operating expense dollars towards providing patient access and finding the lowest cost, highest return on investment means of communicating with the prescribing physicians while also significantly expanding reach and frequency. This commercial model allowed us to be truly therapeutic category agnostic as we executed on our growth strategy to seek additional sources of growth externally. Acquiring products and businesses is an integral part of Assertio's growth strategy and recent success. We have a proven track record of doing it successfully, and I'm confident that we can repeat this success with Spectrum. At this point, I'll turn the call over to Tom Riga to talk about Spectrum, the opportunity for ROLVEDON, and the potential for this transaction to deliver significant value to shareholders. Thanks, Dan. Good morning, everybody, and thank you for joining today's call. Let me start by saying that I am equally as excited about this transformational combination, which we believe will drive the next phase of Spectrum's growth. We look forward to working closely with the Assertio team and realizing the potential for the combined company to deliver value for both the patients we serve and our shareholders. This transaction is both on strategy and positive for shareholders of both companies. Our mission at Spectrum has always been to acquire, develop, and commercialize products that make a positive difference in the lives of cancer patients. With Assertio, we have a partner that will enable us to deliver on that promise. The combination of financial discipline and maximizing ROLVEDON's launch has allowed us to realize our broader strategic vision. As I mentioned in March on our full year 2022 earnings call, we are not complacent being a single product company and aspire to commercialize and develop a portfolio of treatments for patients in need. We believe this combination allows us to execute on that vision as we continue to commercialize ROLVEDON while extracting operational synergies, which Spectrum shareholders will capitalize on through their shared ownership stake in the combined company. We believe the combination allows our business to reach profitability and positive cash flows faster than doing it alone. Importantly, I believe that Spectrum and Assertio have shared values and that both companies are passionate about delivering innovative treatments that can help improve the lives of patients. For Assertio shareholders and those who may be less familiar with Spectrum, we are a commercial stage company that is focused on novel and targeted oncology. We recently launched our product, ROLVEDON, which is a long-acting GCSF for the treatment of chemotherapy-induced neutropenia in the fourth quarter of 2022. ROLVEDON was the first novel product to enter the long-acting GCSF space in over 20 years that is not a biosimilar. Our early launch trajectory of ROLVEDON, with net sales of $10.1 million in the fourth quarter, provided a very positive end to 2022, and that momentum has continued to build throughout the first quarter of 2023. It has been a great start, and the reception we have seen affirms our value proposition and market approach. It's a competitive yet large market. We launched ROLVEDON with a disciplined strategy built upon a thorough understanding of the oncology market and a team with significant experience. As Assertio enters the cancer space with this transaction, they are in good hands with a team with a proven track record of success in oncology. In meeting with Dan and many members of the management team, I believe there is a good cultural fit, and I am impressed by the level of talent and experience at Assertio. They have a clear vision for the company, and I am confident they have the passion, the drive, and the resources to maximize the value of ROLVEDON and create long-term shareholder value for both companies. I will now turn the call back to the operator for Q&A. Thank you. At this time, I would like to remind everyone, in order to ask a question, you must press star and the number 1 on your telephone keypad. Your first question comes from the line of Thomas Flaten with Lake Street. Your line is now open. Good morning. Thanks for taking the questions. Congrats on the transaction. Maybe Tom, if I could start with you, because you've mentioned this is not a biosimilar, is it safe to assume then that you have separate NDC coding, J-codes and that this is a financially attractive molecule for oncologists to use in their practices? Yeah, Tom, great question. This is a full BLA. It is not a biosimilar. I think two significant accomplishments that happened in the fourth quarter and early in the first was inclusion in the NCCN guidelines, as well as a full independent J-code that went into effect April first. You are correct. From a customer profile perspective, I know in your, in your fourth quarter release, you mentioned, you know, 70 accounts and the word community. I'm just curious how sales to date have broken down community versus academic. When we approached this market, we wanted to be very focused in our strategy. The first part was to address the community oncology clinics, which represent about 35% of the market. The reason for that is the receptivity to tailored contracting, the speed of decision-making and the ability to move quickly. That's exactly what we've seen in the concentration of sales. The product will be competitive across all segments of business. When you get into the hospital segment, it's a bit slower. Some of the decision-making from P&P and other aspects of the business take a bit more time. I think the sales that we saw early are absolutely on strategy. We announced at our year-end call, we are starting to see traction within large IDN systems. I really think the combination of these two companies by increasing the reach to some of those outer targets, will certainly allow us to continue to gain velocity. Great. Then, Dan, just kind of listening to your prepared comments, you mentioned near-term visibility and the two products having over $100 million in revenues. I'm not sure if you're providing guidance there, but certainly with a $60 million OpEx add, that would be more consistent with your EBITDA margins if you were a $100 million product. Can you just give us some more color on the 2023 impact? I know it depends on closing date a little bit, but from more of a profiling perspective. I think we can do that once the transaction closes, Thomas. You're kind of on point here. It's really when will it close, and we expect it'll be sometime in the third quarter. That's a broad range, I appreciate. We'll be able to give a more specific feedback on what it will specifically add to the tail end of the year at a later time. Sorry, I had one final one. The $60 million of OpEx that you're adding, can you break that down a little bit for, you know, with respect to, you know, G&A, medical teams, salespeople, account reps? Any detail you can give us on that $60 million of spend. It's largely commercial. Okay. will be the vast bulk of it. In addition to there's some ongoing, pediatric requirements and Phase IV commitments for ROLVEDON that we'll be funding as well in that. Those are the two big components. Excellent. Thanks so much for taking the questions. Congrats again. Your next question comes from Ed White with H.C. Wainwright. Your line is now open. Good morning. Thanks for taking my questions, and congratulations on the deal. Just a question on the CVR. If the sales goals are achieved, when will the CVR be paid? In other words, if the sales goals are achieved before the end of the calendar year, will they be paid within that year or sometime in the future after that? Thank you. Hi, Ed. This is Dan Peisert. The specifics of the CVR will be out a little bit later today, in the Form 8-K. That document will be part of that. In general, it's going to be the following calendar year after things have been reported when it will be paid. Okay, great. Thanks for taking my question. Congratulations again. Your next question comes from Maury Raycroft with Jefferies. Your line is now open. Hi, good morning. Congrats on the update. I also had a question on the CVRs. just in looking at our ROLVEDON estimates for 2024 and 2025, which are a little higher than consensus but lower than the milestones you're aiming to achieve at $175 million and $225 million. Can you talk about your assumptions behind the sales milestone numbers tied to the CVRs and what has to be done to achieve those sales milestones? I can't I'm not prepared to give comments about the specific assumptions, but we, as you probably know better than I, this is a very large market that can easily support that level of sales. As Tom mentioned, they're starting to focus in the community clinics, which is 35% of that market, which is still well above those numbers. We're going to continue with the strategy that the Spectrum team has launched this product with, and it's been a very successful launch to date. As long as things go as planned, we should be able to achieve those targets and reward both shareholders of Assertio and Spectrum. Maury, I guess the only other comment I would make here is some of the attractiveness that we saw in the combination with Assertio and working directly with Dan is the intent and the recognition of the commercial infrastructure, the commercial team, and know-how that exists here within Spectrum. We are confident in our ability to execute on those numbers. Got it. Makes sense. Other question was just if you could talk a little bit more about the commercial synergy or overlap, particularly in oncology or when it comes to experience with 340B or non-340B hospital networks. Also, wanted to check on the appeal of the same-day dosing trial and strategy and how much that factored into the acquisition. Let me just, I think that Tom... Oh, go ahead, Tom. Go ahead. Let me just take this in two parts, Maury. I think from the first part, we have always approached this market with lean infrastructure. I think just some of the dynamics within the market, we've said there's 113 systems that make up 50% of the business. There's about 660 clinics that we're able to focus on within our existing infrastructure, but there are 2,000 across the United States. I think augmenting the non-personal promotion platform will certainly open up new reach and frequency that otherwise we weren't able to get to with the current scale. I think there is a benefit between the two companies' approach as Assertio enters the oncology space. I think regarding the same-day dosing data, you know, we have that in our plan. We're going to see that in the second half of the year. As Dan and I talked about, we are going to see what those results look like and then make that investment decision. Certainly if the data is similar to what we've seen in the early work, it is absolutely advantageous to the assets. I think that's yet to be seen when we get the next data read. Got it. Okay. Thanks for taking my questions. Congrats again. If there are any additional questions from our covering analysts, I would like to remind you to press star 1 to ask your question now. Your final question comes from Hamed Khorsand with BWS Financial. Your line is now open. Hi, good morning. I really just wanted to understand, Dan, holding on to the sales force, is there any synergies there as far as leveraging what Spectrum brings with what the assets Assertio already has? There is some leverage from the existence of the infrastructure, but the commercial team, the sales force and the account managers that are selling ROLVEDON, we want them focused for the time being on ROLVEDON. The synergies will come largely from the contracting and access teams that will be a tremendous benefit to the rest of the Assertio portfolio. Is there enough capacity as far as just manufacturing and working capital to sustain the growth that, you know, is expected in 2024 and 2025? Tom, do you want to answer that? Yeah. I think the short answer is yes. Okay. All right. Very good. Thank you. There are no further questions at this time. Dan Peisert, I turn the call back over to you. Thanks. I, and if I can speak collectively for Assertio, are very excited about the potential combination with Spectrum. In summary, we expect this transaction to enable us to exceed our near-term business development objectives. The addition of ROLVEDON to our portfolio will immediately diversify and accelerate the revenue growth trajectory of Assertio. ROLVEDON is a biologic product competing in a blockbuster market with patent protection extending to 2036. We expect that ROLVEDON will continue to generate in excess of $100 million in annual revenue at attractive margins and be highly accretive to adjusted EBITDA, adjusted EPS, and free cash flow. Thank you for all listening in this morning, and I hope you all have a good day. This concludes today's conference call. You may now disconnect.